

Cadila Pharma unveils arthritis biosimilar drug

28 August 2020 | News

Adalimumab, popular under the brand name Humira® by Abbvie is used to treat rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis and psoriasis



Ahmedabad based Cadila Pharmaceuticals has recently announced the launch of Adalimumab biosimilar under the brand name Cadalimab™ for the domestic market. Adalimumab is a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF?) recommended in the treatment of many diseases.

Adalimumab, popular under the brand name Humira® by Abbvie is used to treat rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis and psoriasis. In an effort to strengthen their the biosimilar product portfolio, Cadalimab™ is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals.

“Around 7 million* people in India suffer from rheumatoid arthritis, while 0.44-2.8%** of people in India suffer from Psoriasis. While these are not life-threatening, Psoriasis and RA can be painful to live with. With the launch of Cadalimab™, we want to reach these patients with a cost-effective solution and give them a chance at a better life.” shared Amit Ajmera, Vice President, Cadila Pharmaceuticals Limited.

“With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. Cadalimab™ comes in an easy pre-filled syringe which makes it easy to use for every patient and provides them relief from disorders such as arthritis and Psoriasis. We are on a journey to expand treatment options with affordable biosimilars”, said Mr. O.P. Singh, President -Sales and Marketing, Cadila Pharmaceuticals Limited.

Cadalimab™ is available in 40mg/0.8ml injection and has shown to have significant reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis after the usage of Cadalimab™.

Cadila Pharmaceuticals recently launched 3 more biosimilar products in the last 2 months under the name Bevaro™, Ritucad™ and NuPTH for treatment of cancer and osteoporosis. The pharma giant has always been focused on making sure high quality, affordable and life-saving treatments are within the reach of patients. Cadila plans to launch multiple biosimilar products this year for the Indian Market.